Le N, Dunleavy M, Kumar R, Zhou W, Bhatia S, El-Hashash A
Am J Stem Cells. 2024; 13(4):191-211.
PMID: 39308764
PMC: 11411253.
DOI: 10.62347/DAKS5508.
Sim J, Moon S, Choi J, Oh J, Lee Y, Min K
Korean J Intern Med. 2024; 39(2):295-305.
PMID: 38326962
PMC: 10918379.
DOI: 10.3904/kjim.2023.273.
Yegen C, Marchant D, Bernaudin J, Planes C, Boncoeur E, Voituron N
Front Physiol. 2023; 14:1205924.
PMID: 37383147
PMC: 10293840.
DOI: 10.3389/fphys.2023.1205924.
Kanvinde S, Deodhar S, Kulkarni T, Jogdeo C
BioTech (Basel). 2023; 12(2).
PMID: 37218751
PMC: 10204512.
DOI: 10.3390/biotech12020034.
Jovanovic D, Sterclova M, Mogulkoc N, Lewandowska K, Muller V, Hajkova M
Respir Res. 2022; 23(1):135.
PMID: 35624513
PMC: 9145164.
DOI: 10.1186/s12931-022-02033-6.
Occurrence of Idiopathic Pulmonary Fibrosis in Italy: Latest Evidence from Real-World Data.
Iommi M, Bonifazi M, Faragalli A, Latini L, Mei F, Spazzafumo L
Int J Environ Res Public Health. 2022; 19(5).
PMID: 35270205
PMC: 8909740.
DOI: 10.3390/ijerph19052510.
Sex Differences in the Incidence and Outcomes of Patients Hospitalized by Idiopathic Pulmonary Fibrosis (IPF) in Spain from 2016 to 2019.
Lopez-Muniz Ballesteros B, Lopez-Herranz M, Lopez-de-Andres A, Hernandez-Barrera V, Jimenez-Garcia R, Carabantes-Alarcon D
J Clin Med. 2021; 10(16).
PMID: 34441772
PMC: 8396834.
DOI: 10.3390/jcm10163474.
All-cause mortality of patients with idiopathic pulmonary fibrosis: a nationwide population-based cohort study in Korea.
Ko S, Choi S, Han K, Lee C, Lee J
Sci Rep. 2021; 11(1):15145.
PMID: 34312485
PMC: 8313530.
DOI: 10.1038/s41598-021-94655-x.
Knockdown of long non‑coding RNA DLEU2 suppresses idiopathic pulmonary fibrosis by regulating the microRNA‑369‑3p/TRIM2 axis.
Yi H, Luo D, Xiao Y, Jiang D
Int J Mol Med. 2021; 47(5).
PMID: 33760118
PMC: 7979258.
DOI: 10.3892/ijmm.2021.4913.
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.
Poletti V, Vancheri C, Albera C, Harari S, Pesci A, Metella R
Respir Res. 2021; 22(1):66.
PMID: 33627105
PMC: 7903602.
DOI: 10.1186/s12931-021-01643-w.
The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities.
Caminati A, Madotto F, Conti S, Cesana G, Mantovani L, Harari S
Intern Emerg Med. 2021; 16(7):1793-1802.
PMID: 33586036
DOI: 10.1007/s11739-021-02651-w.
Epidemiologic Analysis of Taiwanese Patients with Idiopathic Pulmonary Fibrosis.
Yang S, Perng D, Ko H, Chang Y, Hsu C, Huang H
Healthcare (Basel). 2020; 8(4).
PMID: 33371337
PMC: 7767390.
DOI: 10.3390/healthcare8040580.
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
Olson A, Hartmann N, Patnaik P, Wallace L, Schlenker-Herceg R, Nasser M
Adv Ther. 2020; 38(2):854-867.
PMID: 33315170
PMC: 7889674.
DOI: 10.1007/s12325-020-01578-6.
New Perspectives on the Aberrant Alveolar Repair of Idiopathic Pulmonary Fibrosis.
Wang Z, Tang X
Front Cell Dev Biol. 2020; 8:580026.
PMID: 33117807
PMC: 7561442.
DOI: 10.3389/fcell.2020.580026.
Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis.
Ronnow S, Dabbagh R, Genovese F, Nanthakumar C, Barrett V, Good R
Respir Res. 2020; 21(1):108.
PMID: 32381012
PMC: 7203825.
DOI: 10.1186/s12931-020-01369-1.
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue.
Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O
Eur Respir Rev. 2019; 28(153).
PMID: 31578211
PMC: 9488913.
DOI: 10.1183/16000617.0044-2019.
Cell-based therapy for idiopathic pulmonary fibrosis.
Lu Q, El-Hashash A
Stem Cell Investig. 2019; 6:22.
PMID: 31559309
PMC: 6737434.
DOI: 10.21037/sci.2019.06.09.
Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.
Harari S, Davi M, Biffi A, Caminati A, Ghirardini A, Lovato V
Intern Emerg Med. 2019; 15(3):437-445.
PMID: 31541394
DOI: 10.1007/s11739-019-02195-0.
Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Zurkova M, Kriegova E, Kolek V, Lostakova V, Sterclova M, Bartos V
Respir Res. 2019; 20(1):16.
PMID: 30665416
PMC: 6341650.
DOI: 10.1186/s12931-019-0977-2.
Nickle(II) ions exacerbate bleomycin-induced pulmonary inflammation and fibrosis by activating the ROS/Akt signaling pathway.
Yang L, Lin Z, Wang Y, Li C, Xu W, Li Q
Environ Sci Pollut Res Int. 2017; 25(5):4406-4418.
PMID: 29185215
DOI: 10.1007/s11356-017-0525-x.